The Nuclear Factor-Kappa B (NF-κB) transcription factor has been implicated in the pathology of CLL, with high levels of NF-κB associated with disease progression and drug resistance. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.